P atients with type 2 diabetes mellitus have a higher risk of cardiovascular events and death than those without diabetes. [1] [2] [3] [4] Few large, randomized trials have addressed the question of the optimal treatment for patients with diabetes and angiographically defined sta ble ischemic heart disease. The Bypass Angio plasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was designed to test treatment strategies for patients with coronary artery dis ease and diabetes. Our goal was to address the effects of therapy on the rate of myocardial ische mia, a major cause of death in patients with dia betes, and of insulin resistance, the fundamental mechanism underlying diabetes with profound cardiovascular consequences. 5, 6 Among patients with diabetes, studies have indicated that increased insulin levels predict adverse outcomes 7, 8 and that control of hypergly cemia by reducing insulin resistance, rather than by providing insulin, might improve cardiovas cular outcomes. This approach is tempered by data suggesting a limited benefit 9 or possible harm 10,11 associated with the use of newer insu linsensitizing thiazolidinedione drugs and the failure of three recent trials to show reductions in cardiovascular events from intensifying glu cose control beyond the current recommenda tions of the American Diabetes Association. 12 Although the effectiveness of coronary revas cularization in relieving angina is well estab lished, its benefit in reducing the rates of subse quent myocardial infarction and death has been shown only in patients with highrisk profiles 13, 14 or acute coronary syndromes. 15, 16 Studies of cor onary revascularization in patients with moder ate 17 or with mild or no symptoms have had conflicting results. 18, 19 However, such trials have not focused on patients with diabetes, who are at high risk with even mild symptoms of myocar dial ischemia.
Thus, we evaluated two cardiac treatment strategies and two glycemic treatment strategies in patients who were receiving uniform glycemic control and intensive therapy for cardiac risk fac tors. 20 Our first hypothesis was that prompt revas cularization (either surgical or catheterbased) would reduce longterm rates of death and car diovascular events, as compared with medical therapy alone. Our second hypothesis was that a strategy of insulin sensitization (with a target level for glycated hemoglobin of less than 7.0%) would reduce longterm rates of death and car diovascular events, as compared with a strategy of insulin provision.
Me thods

Study Population
From January 1, 2001 1, , to March 31, 2005 , pa tients were enrolled at 49 clinical sites in the United States, Canada, Brazil, Mexico, the Czech Republic, and Austria. Treatment continued until the 6year visit or until the last annual visit before December 1, 2008. Patients who were still en rolled in the trial were contacted between Septem ber and November 2008; national database search es were conducted for patients with unknown vital status.
Eligibility criteria included a diagnosis of both type 2 diabetes and coronary artery disease. The diagnosis of type 2 diabetes was based on the need for treatment with insulin or oral hypogly cemic drugs or a confirmed elevated blood glu cose level. The diagnosis of coronary artery dis ease was documented on angiography (≥50% stenosis of a major epicardial coronary artery associated with a positive stress test or ≥70% stenosis of a major epicardial coronary artery and classic angina). All patients had to be can didates for elective percutaneous coronary inter vention (PCI) or coronaryartery bypass grafting (CABG). Patients were excluded if they required immediate revascularization or had left main coronary disease, a creatinine level of more than 2.0 mg per deciliter (177 μmol per liter), a gly cated hemoglobin level of more than 13.0%, class III or IV heart failure, or hepatic dysfunc tion or if they had undergone PCI or CABG within the previous 12 months.
Treatment Strategies
Patients were randomly assigned to two treat ment strategies in a 2by2 factorial design. In the first strategy, patients were assigned to undergo either prompt coronary revascularization or medi cal therapy. In the second strategy, patients were assigned to undergo either insulinsensitization therapy or insulinprovision therapy to achieve a target glycated hemoglobin level of less than 7.0%. A key feature of the trial was that randomization was stratified according to the method of revas cularization (PCI or CABG), as determined a priori by the responsible physician to be the more appropriate therapy for each patient (Fig. 1) .
Patients in the revascularization group were to undergo the procedure within 4 weeks after randomization, whereas patients in the medical therapy group were to undergo revascularization during followup only if such therapy were clini cally indicated by the progression of angina or the development of an acute coronary syndrome or severe ischemia. 21 Patients in the insulinsensi tization group could receive insulinproviding drugs, and patients in the insulinprovision group could receive insulinsensitizing drugs if the gly cated hemoglobin level could not otherwise be maintained below 8.0%.
All patients were treated according to current guidelines, with a target level for glycated hemo globin of less than 7.0%, a lowdensity lipopro tein (LDL) cholesterol level of less than 100 mg per deciliter (2.6 mmol per liter), and a blood pres sure of 130/80 mm Hg or less. In addition, all patients received counseling regarding smoking cessation, weight loss, and regular exercise. Clin ical management centers monitored and provided feedback on riskfactor control. 22 Patients were seen monthly for the first 6 months and every 3 months thereafter.
Evaluation of Outcomes
The primary end point was death from any cause, and the principal secondary end point was a com posite of death, myocardial infarction, or stroke (major cardiovascular events). The definition of nonfatal myocardial infarction included sponta neous, silent, and procedurerelated events. Accord ing to the study's protocol, 12lead electrocardi ography was performed at baseline, at 3 months, at 1 year, and annually thereafter, before and af ter each revascularization procedure, and at the time of suspected ischemic events. 
Study Design
The trial design and baseline characteristics of the patients have been described previously. [21] [22] [23] [24] [25] The protocol was approved by the institutional review board at the University of Pittsburgh and at each participating site. All patients provided written informed consent. Investigators at 49 clin ical sites collected data, which were analyzed at the University of Pittsburgh. An independent data and safety monitoring board approved the study protocol and monitored the safety of pa tients. The trial was sponsored by the National Institutes of Health, with additional support from industry. Industry sponsors did not have access to outcome data at any time during the trial and did not participate in data analyses or the prepa ration of the manuscript.
Statistical Analysis
We compared baseline characteristics, followup measures, and clinical outcomes on an intention totreat basis according to the randomized study group assignment. Continuous variables were compared with Student's ttest or Wilcoxon non parametric statistics and categorical variables with chisquare statistics. Crosssectional followup data were presented at 3 years, since followup ranged from 3 to 6 years. We compared rates of death and major cardiovascular events using KaplanMeier survival curves and logrank statistics with a twosided alpha level of 0.05. Within strata de fined by the intended method of revasculariza tion, we compared end points in the revascular ization group and the medicaltherapy group using a logrank test at a twosided alpha level of 0.01. 24 Cox proportionalhazards regression mod els that included studygroup assignment, stratum, and assigned study group according to stratum interaction were used to determine whether the studygroup effect was significantly modified by the intended method of revascularization. In ad dition, the statistical interactions between the car diac study groups and the glycemic study groups for rates of death and major cardiovascular events were tested overall and within the PCI and CABG strata at a twosided alpha level of 0.05. Followup data regarding the rate of death were censored at the time of the last contact with the patient, whereas data for the principal secondary end point were censored at the last studyclinic visit. In 2005, the followup period was extended by 1.5 years to increase the average followup to 5.3 years because recruitment of patients took longer than planned and the original target of 2800 patients was not met. The extension was designed to provide a power of 88% to detect a 30% reduction in the rate of death (from 14.0% to 9.8%) and a power of 95% to detect a 25% reduction in the rate of major cardiovascular events (from 24.0% to 18.0%).
R esult s
Patients
All the patients underwent clinically indicated coronary angiography before randomization; most of them provided consent during screening before angiography but after meeting clinical eligibility requirements. Thus, the number of patients who were excluded for reasons unrelated to coronary anatomy is unavailable. Of the 4623 patients with type 2 diabetes who consented to screening, 2187 were ineligible for randomization; 68 eligible pa tients declined to participate, and the remaining 2368 patients underwent randomization. 24 Baseline characteristics were well balanced among the study groups (Table 1 in the Supple mentary Appendix). Myocardial ischemia was symptomatic in 82.1% of patients, and the mean duration of diabetes was 10.4 years. The average followup was 5.3 years, and 2194 patients (92.7%) completed the study as designed (Fig. 1 in the Supplementary Appendix).
Study Treatments
Coronary revascularization was performed with in 6 months in 95.4% of patients in the revascu larization group, as compared with 13.0% of pa tients in the medicaltherapy group ( Fig. 2 in the Supplementary Appendix). At 5 years, 42.1% of patients in the medicaltherapy group (43.3% in the PCI stratum and 39.7% in the CABG stratum) had undergone clinically indicated revasculariza tion. Nearly 90% of patients in both the insulin sensitization group and the insulinprovision group were taking their assigned medications at 3 years, although 43.4% of patients in the insu linsensitization group and 11.8% of those in the insulinprovision group received medications from the alternative drug class to obtain adequate gly cemic control (Fig. 2 in the Supplementary Ap pendix).
Among 765 patients in the revascularization group who underwent PCI, procedures were at tempted on a mean (±SD) of 1.5±0.8 lesions. Of these procedures, 20.7% involved a multivessel intervention; 34.7% of the patients received a drugeluting stent, and 56.0% received a bare metal stent; the other 9.3% did not receive a stent. After drugeluting stents became available in April 2003, 61.0% of the initial PCI procedures involved the use of such stents. Of the 347 pa tients in the revascularization group who under went CABG, 36.0% were treated offpump, and 94.2% received an internal mammaryartery graft; a mean of 3.0±1.0 distal anastomoses were per formed. The 30day rate of death was 0.5% in the PCI subgroup and 1.4% in the CABG sub group; the 30day composite end point of death, myocardial infarction, or stroke occurred in 3.5% of the patients after PCI and in 4.6% after CABG.
At the 3year followup, the most frequently used drugs in the insulinprovision group were insulin (60.7%) and sulfonylurea (52.0%); in the insulinsensitization group, the most frequently used drugs were metformin (74.6%) and a thia zolidinedione (62.1%) ( Table 1) . At 3 years, 5.6% of the patients were being treated for diabetes with diet alone. Throughout followup, the mean glycated hemoglobin levels were significantly lower in the insulinsensitization group than in the insulinprovision group (P<0.001) ( Table 1) .
All patients received intensive medical therapy during the trial in accordance with clinical guidelines, with common use of statins, aspirin, betablockers, and either angiotensinconvertingenzyme inhibitors or angiotensinreceptor block ers (Table 1) . At 3 years, most patients had met treatment goals for levels of LDL cholesterol (82.6%) and blood pressure (71.1%). The body mass index was significantly lower and levels of highdensitylipoprotein (HDL) cholesterol were significantly higher in the insulinsensitization group than in the insulinprovision group dur ing followup (Table 1) .
Primary and Principal Secondary Outcomes
The rates of death from any cause did not differ significantly overall between the revasculariza tion group and the medicaltherapy group or be tween the insulinsensitization group and the insulinprovision group (Fig. 2) . The 5year rate of survival was 88.3% among patients in the revascularization group, as compared with 87.8% among patients in the medicaltherapy group (difference, 0.5%; 95% confidence interval [CI], −2.0 to 3.1; P = 0.97 by the logrank test). At 5 years, the rate of survival was 88.2% among pa tients in the insulinsensitization group, as com pared with 87.9% among patients in the insulin provision group (difference, 0.3%; 95% CI, −2.2 to 2.9; P = 0.89 by the logrank test). The rate of freedom from major cardiovascular events did not differ significantly between the revascular ization group and the medicaltherapy group (difference, 1.3%; 95% CI, −2.2 to 4.9; P = 0.70) or between the insulinsensitization group and the insulinprovision group (difference, 2.4%; 95% CI, −1.2 to 6.0; P = 0.13) (Fig. 2) .
Revascularization Strata
The patients for whom CABG was prespecified as the intended method of revascularization had more extensive coronary disease, 26 with signifi cantly more threevessel disease, proximal dis ease of the left anterior descending artery, and chronic coronary occlusions than the patients for whom PCI was intended. Patients who were se lected to undergo CABG were also more likely to have a history of myocardial infarction and less likely to have undergone previous coronary revas cularization ( PCI stratum (Fig. 3) . Patients in the CABG stra tum who were assigned to the revascularization group had significantly fewer major cardiovas cular events than did patients in the CABG stra tum who were assigned to the medicaltherapy group (P = 0.01) (Fig. 3) . In contrast, rates of cardiovascular events among patients in the PCI stratum who were assigned to the revasculariza tion group did not differ significantly from those who were assigned to the medicaltherapy group (Fig. 3) . The interaction between studygroup assignment and intended method of revascular ization was statistically significant (P = 0.002), which indicated that the benefit associated with prompt coronary revascularization, as compared with medical therapy, was significantly greater for patients selected for CABG than for patients selected for PCI. In the CABG stratum, nonfatal myocardial infarction occurred in markedly few er patients in the revascularization group (7.4%) than in the medicaltherapy group (14.6%) (Ta ble 2 in the Supplementary Appendix).
Evaluation of Treatment Combinations
An analysis of the rates of death and major car diovascular events among the four mutually ex clusive groups -revascularization plus insulin sensitization, revascularization plus insulin pro vision, medical therapy plus insulin sensitiza tion, and medical therapy plus insulin provision -revealed no significant heterogeneity (P>0.05 for interaction) or treatment differences (P>0.05 for all four group comparisons by the logrank test). When the analysis was stratified according to the intended method of revascularization, the rate of major cardiovascular events differed sig nificantly among the four study groups in the CABG stratum (P = 0.02), with the lowest rate seen in the group that underwent revasculariza tion plus insulin sensitization; the interaction between the two treatments was of borderline significance (P = 0.07) ( Table 2 ). The effect of revascularization on the rate of cardiovascular events was particularly evident among patients in the CABG stratum who were assigned to the in sulinsensitizing strategy, with a rate of 18.7% among patients in the revascularization group, as compared with 32.0% among those in the medicaltherapy group (P = 0.002).
Adverse Events
Adverse event rates were infrequent and did not generally differ among the study groups (Table  2) . However, severe hypoglycemia (which was defined as hypoglycemia requiring assistance with treatment and either a blood glucose level of <50 mg per deciliter [2.8 mmol per liter] or con fusion, irrational or uncontrollable behavior, con vulsions, or coma reversed by treatment that There was no significant difference in rates of survival between the revascularization group and the medical-therapy group (Panel A) and between the insulin-sensitization group and the insulin-provision group (Panel B). The rates of major cardiovascular events (death, myocardial infarction, or stroke) also did not differ significantly between the revascularization group and the medical-therapy group (Panel C) or between the insulin-sensitization group and the insulin-provision group (Panel D).
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raises blood glucose levels) was more frequent among patients assigned to receive insulin provi sion (9.2%) than among those who received insu lin sensitization (5.9%, P = 0.003). Among patients with no history of heart failure, the rate of new congestive heart failure did not differ signifi cantly between patients in the insulinsensitiza tion group (19.4%) and those in the insulinpro vision group (16.6%, P = 0.09). Peripheral pitting edema was more frequent in the insulinsensiti There was no significant difference in rates of survival between the revascularization group and the medical-therapy group among patients who were selected for the percutaneous coronary intervention (PCI) stratum (Panel A) or among those who were selected for the coronaryartery bypass grafting (CABG) stratum (Panel B). The rates of freedom from major cardiovascular events (death, myocardial infarction, or stroke) also did not differ significantly between the revascularization group and the medical-therapy group among patients in the PCI stratum (Panel C), but the rates were significantly better among patients in the revascularization group than in the medical-therapy group within the CABG stratum (Panel D).
zation group than in the insulinprovision group (P = 0.02).
Discussion
Among patients with type 2 diabetes and stable ischemic heart disease receiving intensive medi cal therapy, there was little difference between insulin sensitization and insulin provision with respect to rates of death and cardiovascular events at 5 years. Likewise, a strategy of prompt coronary revascularization with the procedure most appropriate for the individual patient and a strategy of medical therapy led to similar clinical outcomes. Prompt revascularization significantly reduced major cardiovascular events, as compared with intensive medical therapy, among patients who were selected to undergo CABG but not among those who were selected to undergo PCI. Our study was designed to compare coronary revascularization with intensive medical therapy, not to compare CABG with PCI. Patients who were selected to undergo CABG were expected to have higher event rates; indeed, among patients who were assigned to the medicaltherapy group in the CABG stratum, the 5year mortality (16.4%) was much higher than that among patients as signed to medical therapy in the PCI stratum (10.2%).
The study was designed to reflect how physi cians might confront treatment decisions in prac tice. Our findings suggest that patients who have diabetes, evidence of myocardial ischemia, and extensive multivessel disease would benefit from prompt surgical revascularization mainly because of a lower rate of nonfatal myocardial infarction. However, for the many patients with type 2 dia betes who have less extensive coronary disease and for whom PCI is judged to be more appro priate, prompt revascularization did not reduce the risk of cardiovascular events, as compared with medical therapy. Approximately one third of patients in the PCI stratum who were assigned to undergo revascularization received a drug eluting stent, but since these devices have not been shown to reduce rates of death or major cardiovascular events, 27 their use probably did not affect the results. patients were in the percutaneous coronary intervention (PCI) stratum, and 763 were in the coronaryartery bypass grafting (CABG) stratum. † Except where otherwise noted, the P value is for the comparison between the revascularization group and the medicaltherapy group. ‡ Except where otherwise noted, the P value is for the comparison between the insulin-sensitization group and the insulin-provision group. § The P value is for the interaction between the cardiac study group and the glycemic study group. ¶ In the CABG stratum, the rate of major cardiovascular events differed significantly (P = 0.02) among the four mutually exclusive randomized study groups.
It is important to note that all the patients who were assigned to receive medical therapy underwent careful clinical monitoring, and 42.1% had changes in the clinical course that called for later revascularization during 5 years of follow up. In clinical practice, the initial treatment strategy for a patient with diabetes and coronary disease rarely remains constant over a 5year period. The fact that most patients in the medi caltherapy group did not require coronary revas cularization during the 5year period suggests that many patients may be safely treated with intensive medical therapy.
Our twobytwo factorial design allowed further comparisons between combinations of strategies. Among patients for whom CABG was selected as the intended method of revascularization, the combination of prompt revascularization and an insulinsensitization strategy was associated with a significantly lower rate of major cardiovascular events than any of the other three treatment com bination groups. Although previous studies have shown a beneficial effect on cardiovascular out comes associated with the use of insulin sensiti zation with thiazolidinedi ones 9, 28, 29 and metform in, 30 our results cannot distinguish between the effect of either agent or the combination.
The strategies for glycemic control that we tested were not implemented at the time of ini tial diagnosis of diabetes, and there was inevita bly less than complete differentiation of treat ment regimens. The treatment regimens in our study reflect what is clinically possible for pa tients with established type 2 diabetes. Intensi fication of medical therapy and consistent mon itoring led to improved control of cardiac risk factors across the board. Although only 28.4% of patients simultaneously achieved all three proto col targets at 3 years, the rates of control attained in this trial were much better than the rates re corded for community care 31,32 and similar to those reported in other trials. 33, 34 The mean followup glycated hemoglobin val ues in the insulinsensitization group and the insulinprovision group were close to the target level of 7.0% but differed significantly from each other. The mean difference of less than 0.5% in glycated hemoglobin levels between the two gly cemiccontrol strategies in our study was less than the mean difference of 1.6% in the Veterans Affairs Diabetes Trial (VADT) (ClinicalTrials.gov number, NCT00032487), 33 the difference of 1.1% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (NCT00000620), 35 and the difference of 0.6% in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial (NCT00145925). 34 Since none of these trials that compared different glycemiccontrol targets showed a significant reduction in cardiovascular events, it is unlikely that our results were due solely to differences in the level of glycemic control.
In our study, plasma insulin levels were con sistently lower over time in patients in the insulin sensitization group (median, 6.3 μU per milli liter) than in those in the insulinprovision group (median, 10.0 μU per milliliter), a finding that is consistent with the mechanisms of action of metformin and thiazolidinediones. Despite the need to administer insulin or sulfonylureas to some patients, patients in the insulinsensitization group were maintained at or very near the target level for glycated hemoglobin. Moreover, the in sulinsensitization strategy was associated with fewer severe hypoglycemic episodes, less weight gain, and higher HDL levels than those in the insulinprovision strategy. These data may suggest that insulin sensitization is preferable for patients with type 2 diabetes and coronary disease.
Like all randomized clinical trials, our study was limited in terms of the generalizability of results to all patients with type 2 diabetes and coronary disease. Furthermore, confidence inter vals for the overall betweengroup differences were within 3% for the rate of death and 6% for the rate of major cardiovascular events; smaller treatment effects could have been missed. In summary, a strategy of prompt coronary revascularization in patients who had been treat ed with intensive medical therapy for diabetes and stable ischemic disease did not significantly reduce the rate of death from any cause or of major cardiovascular events. Insulin sensitization and insulin provision also had similar cardiovas cular outcomes during a 5year period. Among patients for whom CABG was deemed to be the appropriate treatment, prompt revascularization reduced the rate of major cardiovascular events, as compared with medical therapy, particularly among patients who were assigned to receive in sulin sensitization. In the PCI stratum, however, revascularization did not reduce the rate of death or major cardiovascular events when added to medical therapy. 
